New Trends in Bladder Cancer Management{A figure is presented}

European Urology, Supplements

Volumn 6, Issue 4, 2007, Pages 388-395

  Irani, Jacques ^a   Mottet, Nicolas ^b   Ribal Caparrós, María Jose ^c   Teillac, Pierre ^d  

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b Clinique Mutualite   (France)

^c UNIVERSITY OF BARCELONA   (Spain)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

Bacillus Calmette Gu rin; Bladder cancer; EORTC tables; Hospital volume; Interferon ; Invasive; Mitomycin; Quality of life; Superficial; Time to cystectomy; Upper urinary tract tumours

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; BIOLOGICAL MARKER; GEMCITABINE; MESSENGER RNA; MITOMYCIN C; NUCLEAR MATRIX PROTEIN 22; SURVIVIN; TELOMERASE REVERSE TRANSCRIPTASE;

BLADDER CANCER; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER RESEARCH; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; DISEASE FREE SURVIVAL; HUMAN; MEDICAL EXPERT; MEDICAL LITERATURE; MEDICAL SOCIETY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PUBLICATION; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SUPERFICIAL CANCER; SURVIVAL RATE; TUMOR NECROSIS;

EID: 33846662958     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.12.010     Document Type: Review

References (28)

1. Pashos C.L., Botteman M.F., Laskin B.L., et al. Bladder cancer: epidemiology, diagnosis, and management. Cancer Pract 10 (2002) 311-322
2. Planz B., Jochims E., Deix T., et al. The role of urinary cytology for detection of bladder cancer. Eur J Surg Oncol 31 (2005) 304-308
3. Campos-Fernandes J.L., Descotes F., Decaussin M., et al. Urinary survivin is a biomarker for the diagnosis of invasive bladder cancer. Eur Urol Suppl 5 (2006) 114 (abstract no. 366)
4. Pesl M., Babjuk M., Soukup V., et al. Urine survivin in non-invasive diagnosis of transitional cell carcinoma of the urinary bladder. Eur Urol Suppl 5 (2006) 228 (abstract no. 822)
5. Weikert S., Christoph F., Kempkensteffen C., et al. Comparison of survivin, telomerase subunits, and cytology for the noninvasive detection of bladder cancer. Eur Urol Suppl 5 (2006) 228 (abstract no. 824)
6. Shariat S., Ashfaq R., Sagalowsky A., et al. Survivin expression is associated with bladder cancer presence, stage, progression and mortality. Eur Urol Suppl 5 (2006) 252 (abstract no. 920)
7. Fiala R., Stejskal D., Vidlar A., et al. Evaluation of five potential tumour markers for urinary bladder cancer - endostatin, midkine, survivin, livin and E-FABP. Eur Urol Suppl 5 (2006) 253 (abstract no. 922)
8. Liou L.S. Urothelial cancer biomarkers for detection and surveillance. Urology 67 (2006) 25-33
9. Tritschler S., Scharf S., Karl A., et al. Evaluation of the diagnostic value of NMP-22 bladder tumour test by means of fluorescence cystoscopy. Eur Urol Suppl 5 (2006) 255 (abstract no. 929)
10. Barton Grossman H., and the NMP22 Clinical Investigation Group. Initial diagnosis of bladder cancer using a point-of-care assay. Eur Urol Suppl 5 (2006) 137 (abstract no. 460)
11. ® assay in the detection of urinary transitional cell carcinoma. Eur Urol Suppl 5 (2006) 228 (abstract no. 823)
12. Witjes J.A. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 49 (2006) 790-797
13. Gallagher B.L., Joudi F.N., and O'Donnell M.A. Response to intravesical immunotherapy in BCG naïve and BCG treated patients. J Urol 175 (2006) 268 (abstract no. 831)
14. Maymi J.L., Saltsgaver N., and O'Donnell M.A. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. J Urol 175 (2006) 271 (abstract no. 840)
15. Di Stasi S.M., Giannantoni A., Giurioli A., et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Lancet Oncol 7 (2006) 43-51
16. Sylvester R., van der Meijden A.P.M., Oosterlinck W., et al. Predicting recurrence and progression in stage Ta T1 bladder cancer patients using EORTC risk tables. J Urol 175 (2006) 269 (abstract no. 834)
17. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477
18. May M., Nitzke T., Helke C., et al. Significance of the time period between diagnosis of muscle invasion and radical cystectomy with regard to the prognosis of transitional cell carcinoma of the urothelium in the bladder. Scand J Urol Nephrol 38 (2004) 231-235
19. Cathcart P., Armitage J., and Emberton M. Time to cystectomy - its influence on overall survival. Eur Urol Suppl 5 (2006) 24 (abstract no. 6)
20. Ali-el-Dein B., Abdel-Latif M., Mosbah A., et al. Survival following cystectomy for primary muscle invasive bladder transitional cell carcinoma versus invasion on top of superficial disease. Eur Urol Suppl 5 (2006) 24 (abstract no. 7)
21. Nielsen M.E., Shariat S.F., Karakiewicz P.I., et al. Delay in radical cystectomy over 12 weeks is not associated with adverse outcome: results from the bladder cancer research consortium. J Urol 175 (2006) 396 (abstract no. 1231)
22. Fahmy N., Jeyaganth S., Mahmud S., et al. Pre-operative delays prior to cystectomy for bladder cancer: population-based study in Quebec. J Urol 175 (2006) 10-11 (abstract no. 29)
23. Cathcart P.J., Nuttall M., van der Meulen J., et al. The impact of hospital provider volume on the outcome of radical cystectomy in the UK. J Urol 175 (2006) 8 (abstract no. 22)
24. Hollenbeck B.K., Wei Y., Birkmeyer J.D., et al. High volume hospitals do not have better long term outcomes following cystectomy for bladder cancer. J Urol 175 (2006) 8-9 (abstract no. 23)
25. Wei J.T., Dunn R.L., Gilbert S.M., et al. Development and validation of the bladder cancer index (BCI): a disease specific measure of quality of life. J Urol 175 (2006) 12-13 (abstract no. 35)
26. Gilbert S.M., Wood Jr. D.P., Weizer A.Z., et al. Measuring health-related quality of life outcomes in bladder cancer patients using the newly validated bladder cancer index (BCI). J Urol 175 (2006) 13 (abstract no. 36)
27. Zigeuner R., Hutterer G., Chromecki T., et al. Biological significance of squamous and glandular differentiation in urothelial cell carcinoma of the upper urinary tract. Eur Urol Suppl 5 (2006) 136 (abstract no. 456)
28. Langner C., Hutterer G., Chromecki T., et al. Tumour necrosis as prognostic indicator in urothelial carcinoma of the upper urinary tract. Eur Urol Suppl 5 (2006) 137 (abstract no. 457)